Navigation Links
Accium BioSciences Announces $99 Sample Pricing for Its Accelerator Mass Spectrometry (AMS) Measurement Service
Date:10/19/2010

SEATTLE, Oct. 19 /PRNewswire/ -- Accium BioSciences, a leading provider of bioanalytical accelerator mass spectrometry (AMS) services in North America, announced today new pricing for its AMS measurement service at $99 per sample. GLP-compliant service is now available at $115 per sample. The new pricing includes sample graphitization and AMS measurement services. Accium will continue to provide expert bioanalytical and quality assurance services at competitive rates.

"This new pricing is designed to reach a broader research market and is the result of Accium's expanded capacity and steadfast focus on operational efficiencies," said Ali Arjomand, Ph.D., Accium's President and Chief Operating Officer.

Concurrent with this announcement, Accium is launching the DirectAMS™ Program, a streamlined service for customers who only seek graphitization and AMS services. For the first time, such customers may submit samples directly to the AMS Services Unit, bypassing Accium's bioanalytical service offerings. The fee for this service is also $99 (non-GLP) and $115 (GLP) and includes standard reporting of results. As an optional add-on to this program, Accium is providing an enabling service to anyone who seeks to establish their own independent bioanalytical laboratory. The $12,500 annual subscription package includes Accium's up-to-date SOP library, 12 hours of consulting and Accium's Monitoring Kit that includes 40 AMS measurements. The academic/non-profit rate is $7,500 per year and includes six hours of consulting, Accium's SOP library and 40 AMS measurements. This subscription program is ideally suited for academic groups and contract research organizations who can now gain seamless access to quality AMS service at $99/$115 per sample. The fees announced today apply to all samples and study types with the exception of absolute bioavailability (IV microtracer) studies performed at Accium.

"We are well positioned to work with new market segments to apply the power of Accium's AMS-based services in ways that will positively impact research and drive new innovations across the healthcare spectrum," stated Dr. Glenn Kawasaki, Accium's Chief Executive Officer.

For more information, please contact Ali Arjomand of Accium BioSciences at (206)281-3915 x301 (8AM-6PM PDT).

info@acciumbio.com

www.acciumbio.com

About Accium BioSciences

Accium BioSciences is a privately-held company offering ultrasensitive bioanalytical services to the global pharmaceutical industry, including five of the top ten largest pharmaceutical companies. Accium's accelerator mass spectrometry (AMS) services has primarily aided the investigation of drug candidates in preclinical and early clinical development.


'/>"/>
SOURCE Accium BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
(Date:1/19/2017)... 2017  Magnetic Insight Inc., leader in magnetic ... agreement with inviCRO LLC to develop intuitive image ... based on inviCRO,s VivoQuant™ visualization and post processing ... complete MPI solution package with the Momentum MPI ... imaging in vivo. MPI is a ...
(Date:1/18/2017)... 18, 2017  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and ... an underwritten public offering of units for gross ... discounts and commissions and offering expenses payable by ... Class A Units, priced at a public offering ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 2017 , ... Tribble Insurance Agency, a family owned and operated firm offering ... charity event to honor Chad Phillip Dermyer, a local police trooper who was shot ... and his fellow officers were conducting routine stops of suspects when one of them, ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second consecutive year, ... Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, ... been chosen by their peers for the 2017 list based on their exceptional ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales ... market. , Over the past 20 years SFI has been recognized as the world’s ... six new clients into the US market. The new clients include: Panacea Pro, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known ... Few people know that popular cosmetic fillers can enhance earlobes and ... medical director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
Breaking Medicine News(10 mins):